Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and more nuanced than headlines suggest. Whether this path is right for you...
Quick answer: A LSD For Anxiety randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation developed by MindMed, produced significant reductions in generalized anxiety disorder symptoms...
Quick answer: The FDA declined to approve MDMA-assisted therapy for PTSD, citing gaps in safety data, questions about how long the benefits last, and concerns about who was enrolled in the trials. The rejection letter is now public. It does not mean MDMA therapy is...
Ketamine therapy preparation is not a formality. It’s a functional part of what makes the treatment work. Ketamine can produce meaningful shifts quickly, but lasting benefit depends on what happens before the session and after it. This guide covers what to...
When Nico sat across from his psychiatrist after trying yet another antidepressant that didn’t work, he wasn’t angry—he was numb. Thirty years of depression had taught him to live in grayscale. Therapy, medications, even TMS had provided temporary relief, but...
RFK Jr. psychedelic therapy support has brought significant new attention to substances like psilocybin, MDMA, and ibogaine as legitimate tools for mental health care. For seekers who have been quietly researching this space, the political shift is real but so is the...
